ArticleScience signaling2018
The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Abstract read
In one paragraph
Article in Science signaling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Non-coding RNAs in drug and radiation resistance of bone and soft-tissue sarcoma: a systematic review.eLife · 2022Pooled it
- PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells.Cancers · 2026Article
- A Pax7::Foxo1 conditional mouse strain.Skeletal muscle · 2026Article
- Noncoding RNAs in Pediatric Solid Tumors: Advances in Understanding and Critical Knowledge Gaps.Cells · 2026Review
- From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment.Frontiers in cell and developmental biology · 2026Review
- Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls.International journal of molecular sciences · 2025Review
- Ephrin-A5 or EphA7 stimulation is anti-proliferative for human rhabdomyosarcoma in vitro.Skeletal muscle · 2025Article
- Dysregulation of miRNAs in Soft Tissue Sarcomas.Cells · 2024Review
- Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.Biomedicines · 2024Review
- Entinostat as a combinatorial therapeutic for rhabdomyosarcoma.Scientific reports · 2024Article
- HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks.Cell death discovery · 2024Article
- Developmental and therapeutic implications of IL4ra expression for rhabdomyosarcoma.Transgenic research · 2024Article
- Biological and therapeutic insights from animal modeling of fusion-driven pediatric soft tissue sarcomas.Disease models & mechanisms · 2024Review
- Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers.Nature medicine · 2024Observational
- Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma.Scientific reports · 2023Article
- Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas.Pediatric blood & cancer · 2023Article
- Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- MicroRNAs in the Pathogenesis, Prognostication and Prediction of Treatment Resistance in Soft Tissue Sarcomas.Cancers · 2023Review
- The epigenetic regulatory effect of histone acetylation and deacetylation on skeletal muscle metabolism-a review.Frontiers in physiology · 2023Review
- A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 14 institutions in 2 countries.
Narendra BharathyChildren's Cancer Therapy Development Institute, Beaverton, OR 97005, USA.
Noah E BerlowChildren's Cancer Therapy Development Institute, Beaverton, OR 97005, USA.ORCID 0000-0001-8666-3152
Eric WangCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Jinu AbrahamDepartment of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0003-1884-8395
Teagan P SettelmeyerChildren's Cancer Therapy Development Institute, Beaverton, OR 97005, USA.
Jody E HooperDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-8209-3559
Matthew N SvalinaChildren's Cancer Therapy Development Institute, Beaverton, OR 97005, USA.
Yoshihiro IshikawaResearch Center, Shriners Hospital for Children, Portland, OR 97239, USA.ORCID 0000-0003-2013-0518
Keith ZientekResearch Center, Shriners Hospital for Children, Portland, OR 97239, USA.
Zia BajwaChildren's Cancer Therapy Development Institute, Beaverton, OR 97005, USA.
Martin W GorosDepartment of Epidemiology and Biostatistics, University of Texas Health Science Center, San Antonio, TX 78229, USA.ORCID 0000-0002-1388-9000
Brian S HernandezDepartment of Epidemiology and Biostatistics, University of Texas Health Science Center, San Antonio, TX 78229, USA.ORCID 0000-0003-4667-5954
Johannes E WolffDepartment of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children's, Cleveland, OH 44195, USA.
Michelle A RudekDepartment of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.
Linping XuDepartment of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.
Nicole M AndersDepartment of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.
Ranadip PalElectrical and Computer Engineering, Texas Tech University, Lubbock, TX 79409, USA.
Alexandria P HarroldChildren's Cancer Therapy Development Institute, Beaverton, OR 97005, USA.ORCID 0000-0003-3511-3964
Angela M DaviesChampions Oncology, Rockville, MD 20850, USA.
Arya AshokChampions Oncology, Rockville, MD 20850, USA.ORCID 0000-0002-9887-136X
Darnell BushbyChampions Oncology, Rockville, MD 20850, USA.
Maria ManciniChampions Oncology, Rockville, MD 20850, USA.ORCID 0000-0001-9379-7335
Christopher NoakesChampions Oncology, Rockville, MD 20850, USA.
Neal C GoodwinChampions Oncology, Rockville, MD 20850, USA.ORCID 0000-0002-1117-1740
Peter OrdentlichSyndax Pharmaceuticals, Waltham, MA 02451, USA.ORCID 0000-0002-6339-0996
James KeckThe Jackson Laboratory, Sacramento, CA 95838, USA.
Douglas S HawkinsSeattle Children's Hospital, Seattle, WA 98105, USA.ORCID 0000-0003-3602-1375
Erin R RudzinskiSeattle Children's Hospital, Seattle, WA 98105, USA.
Bishwanath ChatterjeeCancer Molecular Pathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892-1500, USA.ORCID 0000-0003-2390-2966
Hans Peter BächingerResearch Center, Shriners Hospital for Children, Portland, OR 97239, USA.
Frederic G BarrCancer Molecular Pathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892-1500, USA.
Jennifer LiddleDepartment of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Benjamin A GarciaDepartment of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Atiya MansoorDepartment of Pathology, Oregon Health & Science University, Portland, OR 97239, USA.
Theodore J PerkinsRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.
Christopher R VakocCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Joel E MichalekDepartment of Epidemiology and Biostatistics, University of Texas Health Science Center, San Antonio, TX 78229, USA.ORCID 0000-0003-3021-773X
Charles KellerChildren's Cancer Therapy Development Institute, Beaverton, OR 97005, USA. charles@cc-tdi.org.ORCID 0000-0003-2505-7487
Champions Oncology (United States) · USChildren's Cancer Therapy Development Institute · USJohns Hopkins University · USOregon Health & Science University · USThe University of Texas Health Science Center at San Antonio · USCold Spring Harbor Laboratory · USNational Cancer Institute · USSeattle Children's Hospital · USShriners Hospitals for Children - Portland · USUniversity of Pennsylvania · USCleveland Clinic · USJackson Laboratory · USTexas Tech University · USUniversity of Ottawa · CA
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6MInstitute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MShared Resources Core 2: Quantitative Proteomics CoreP01CA196539 · NCI · ROCKEFELLER UNIVERSITY · PI MUIR, TOM · 2015 to 2024
$17.6MStudies of gene fusions in rhabdomyosarcomaZIABC011387 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BARR, FREDERIC · 2011 to 2025
$9.1MCytokine- and Satellite Cell-mediated Muscle Disease PromotionR01CA189299 · NCI · CHILDREN'S CANCER THERAPY DEVELOP/INST · PI KELLER, CHARLES · 2015 to 2019
$1.7MElucidating the role of NF-kB signaling in rhabdomyocarcomaR01CA143082 · NCI · OHIO STATE UNIVERSITY · PI GUTTRIDGE, DENIS C, KELLER, CHARLES · 2011 to 2015
$1.6MUnderstanding the Role of Combinatorial Histone PTM PatternsR01GM110174 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI GARCIA, BENJAMIN A · 2014 to 2017
$1.3MNCATS NIH HHS UL1 TR001079NCI NIH HHS P01 CA196539NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA143082NCI NIH HHS R01 CA189299NIGMS NIH HHS R01 GM110174
Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an unmet clinical need for decades. A single oncogenic fusion gene is associated with treatment resistance and a 40 to 45% decrease in overall survival. We previously showed that expression of this
Indexed as
AnimalsAntineoplastic AgentsBenzamidesCell Line, TumorComputational BiologyDNA HelicasesDrug Resistance, NeoplasmEpigenesis, GeneticFemaleFluorescence Resonance Energy TransferForkhead Box Protein O1Gene Expression ProfilingGene Expression Regulation, NeoplasticGene SilencingHistone Deacetylase 3Histone Deacetylase InhibitorsAntineoplastic AgentsBenzamidesDNA HelicasesentinostatForkhead Box Protein O1Foxo1 protein, mouseHistone Deacetylase 3Histone Deacetylase InhibitorsHistone DeacetylasesMicroRNAsMIRN27 microRNA, humanMirn27 microRNA, mouseNuclear ProteinsOncogene Proteins, FusionPaired Box Transcription FactorsPAX3-FOXO1A fusion protein, humanPAX3-FOXO1A fusion protein, mousePax3 protein, mousePAX3 Transcription FactorPyridinesSMARCA4 protein, humanSmarca4 protein, mouseTranscription FactorsVincristine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.